Given its high degree of expression on CTCs in men with prostate cancer and its correlation with poor clinical outcome [17–20], immunotherapies that utilize B7-H3 as a targeting mechanism might have success in upregulating endogenous T-cell response against aggressive tumors. Here, CD276 is linked to prostate cancer.